If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== Metallocenophanes === Metallocenophanes feature linking of the cyclopentadienyl or polyarenyl rings by the introduction of one or more heteroannular bridges. Some of these compounds undergo thermal ring-opening polymerizations to give soluble high molecular weight polymers with transition metals in the polymer backbone. Ansa-metallocenes are derivatives of metallocenes with an intramolecular bridge between the two cyclopentadienyl rings.
In March 2020, UPS expanded its autonomous trips with TuSimple by adding an extra route between Phoenix and El Paso, Texas. In January 2021, UPS announced it had agreed to sell UPS Freight, its less-than-truckload freight business, to TFI International, a Canadian transport and logistics company, for $800 million. UPS said the move would allow it to focus on small-package delivery. At the time of the sale, UPS Freight had about 14,500 employees, approximately 11,000 of them represented by the Teamsters union, and generated an estimated $3.15 billion in revenue in 2020 offering services across the US, Canada, and Mexico. TFI had reported $4.1 billion in revenue in 2019 and already operated truckload and LTL services in Canada. The acquisition was completed in April and UPS Freight was renamed TForce Freight. In 2021, following the company's shift to target smaller customers to boost profits during the COVID-19 pandemic, UPS reported a 21% jump in their fourth quarter sales to $24.9 billion. CEO Carol Tomé reported that Amazon paid UPS $11.3 billion in shipping in 2020, accounting for 13.3% of the company's revenue. In September 2021, UPS entered into an agreement to acquire Roadie for an undisclosed amount with the transaction expected to be closed in the fourth quarter. In May 2022, UPS acquired logistics company Delivery Solutions, a key partner for Walmart's GoLocal network. In November 2022, it was announced UPS had acquired the healthcare focused, Europe-based warehousing and temperature-controlled transport company, Bomi Group.
Since its 1947 independence, India has significantly reduced historically endemic diseases, though some remain intractable. The country was certified smallpox-free in April 1977 following two years of surveillance after its last Variola major case. It was officially certified polio-free by the World Health Organisation on 27 March 2014, after successfully completing three consecutive years without recorded cases of wild poliovirus. In contrast, cholera remains endemic to Ganges-Meghna Delta estuaries, resulting in seasonal outbreaks caused by monsoons and water supply network shortcomings. Tuberculosis is a major concern; India bears a quarter of the global tuberculosis disease burden. Historical malaria cases have dropped from millions to hundreds of thousands annually, but India experiences localised seasonal increases caused by drug-resistant variants of the Plasmodium falciparum and Plasmodium vivax vectors. Patients in India often face a stark choice: use basic, free, publicly funded health care or pay high out-of-pocket fees for better-equipped care from private doctors and hospitals. This divide is particularly severe outside cities, as public clinics in rural areas rarely have enough doctors or nurses to meet local demands. When serious medical emergencies occur, poorer families are often forced to sell land or take out high-interest loans to pay for private care. This resulting medical debt pushes approximately 55 million people into poverty every year.
Sources: en.wikipedia.org
==== Joint injections ==== Intra-articular injections of steroids, hyaluronic acid, or platelet-rich plasma may be used for pain relief in people with knee osteoarthritis. Local drug delivery by intra-articular injection may be more effective and safer in terms of increased bioavailability, less systemic exposure and reduced adverse events. Several intra-articular medications for symptomatic treatment are available.
The redox reactions catalyzed by oxidoreductases are vital in all parts of metabolism, but one particularly important area where these reactions occur is in the release of energy from nutrients. Here, reduced compounds such as glucose and fatty acids are oxidized, thereby releasing energy. This energy is transferred to NAD+ by reduction to NADH, as part of beta oxidation, glycolysis, and the citric acid cycle. In eukaryotes the electrons carried by the NADH that is produced in the cytoplasm are transferred into the mitochondrion (to reduce mitochondrial NAD+) by mitochondrial shuttles, such as the malate-aspartate shuttle. The mitochondrial NADH is then oxidized in turn by the electron transport chain, which pumps protons across a membrane and generates ATP through oxidative phosphorylation. These shuttle systems also have the same transport function in chloroplasts. Since both the oxidized and reduced forms of nicotinamide adenine dinucleotide are used in these linked sets of reactions, the cell maintains significant concentrations of both NAD+ and NADH, with the high NAD+/NADH ratio allowing this coenzyme to act as both an oxidizing and a reducing agent. In contrast, the main function of NADPH is as a reducing agent in anabolism, with this coenzyme being involved in pathways such as fatty acid synthesis and photosynthesis. Since NADPH is needed to drive redox reactions as a strong reducing agent, the NADP+/NADPH ratio is kept very low. Although it is important in catabolism, NADH is also used in anabolic reactions, such as gluconeogenesis.
=== Religious organizations === Celtic Reconstructionism, a form of Polytheism Congregation of Clerics Regular of the Divine Providence (Theatines), a Roman Catholic religious order Community of the Resurrection, an Anglican religious order Congregation of the Resurrection, a Catholic religious order
=== Dicamba lawsuit === On 27 January 2020, the first-ever lawsuit concerning Dicamba-related products began in Cape Girardeau, Missouri. The lawsuit involved a peach farmer who alleged that Dicamba-based herbicides caused significant damage to his crops and trees. It had also been filed in November 2016, when Dicamba was still owned by Monsanto. On 14 February 2020, the jury involved in the lawsuit ruled against BASF and its co-defendant Bayer, which had acquired Monsanto and its products, and found in favor of the peach grower, Bader Farms owner Bill Bader. BASF and Bayer were also ordered to pay Bader $15 million in damages. On 15 February 2020, Monsanto and BASF were ordered to pay an additional $250 million in punitive damages.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.